MedTrace Logo

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

NCT02966145 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 293

Last updated 2025-04-13

No results posted yet for this study

Summary

The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.

Conditions

  • Corticobasal Degeneration (CBD)
  • Corticobasal Syndrome (CBS)
  • Cortical-basal Ganglionic Degeneration (CBGD)
  • Progressive Supranuclear Palsy (PSP)
  • Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
  • Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)

Interventions

OTHER

Observational Study

Sponsors & Collaborators

Principal Investigators

  • Adam L Boxer, MD, PhD · University of California, San Francisco

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2024-02-28
Completion
2024-02-28

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02966145 on ClinicalTrials.gov